The Familial Intracranial Aneurysm (FIA) study protocol

Joseph P. Broderick, Laura R. Sauerbeck, Tatiana Foroud, John Huston, Nathan Pankratz, Irene Meissner, Robert D. Brown

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Background: Subarachnoid hemorrhage (SAH) due to ruptured intracranial aneurysms (IAs) occurs in about 20,000 people per year in the U.S. annually and nearly half of the affected persons are dead within the first 30 days. Survivors of ruptured IAs are often left with substantial disability. Thus, primary prevention of aneurysm formation and rupture is of paramount importance. Prior studies indicate that genetic factors are important in the formation and rupture of IAs. The longterm goal of the Familial Intracranial Aneurysm (FIA) Study is to identify genes that underlie the development and rupture of intracranial aneurysms (IA). Methods/Design: The FIA Study includes 26 clinical centers which have extensive experience in the clinical management and imaging of intracerebral aneurysms. 475 families with affected sib pairs or with multiple affected relatives will be enrolled through retrospective and prospective screening of potential subjects with an IA. After giving informed consent, the proband or their spokesperson invites other family members to participate. Each participant is interviewed using a standardized questionnaire which covers medical history, social history and demographic information. In addition blood is drawn from each participant for DNA isolation and immortalization of lymphocytes. High- risk family members without a previously diagnosed IA undergo magnetic resonance angiography (MRA) to identify asymptomatic unruptured aneurysms. A 10 cM genome screen will be performed to identify FIA susceptibility loci. Due to the significant mortality of affected individuals, novel approaches are employed to reconstruct the genotype of critical deceased individuals. These include the intensive recruitment of the spouse and children of deceased, affected individuals. Discussion: A successful, adequately-powered genetic linkage study of IA is challenging given the very high, early mortality of ruptured IA. Design features in the FIA Study that address this challenge include recruitment at a large number of highly active clinical centers, comprehensive screening and recruitment techniques, non-invasive vascular imaging of high-risk subjects, genome reconstruction of dead affected individuals using marker data from closely related family members, and inclusion of environmental covariates in the statistical analysis.

Original languageEnglish
Article number17
JournalBMC Medical Genetics
Volume6
DOIs
StatePublished - Apr 26 2005

Fingerprint

Intracranial Aneurysm
Ruptured Aneurysm
Aneurysm
Rupture
Genome
Genetic Linkage
Mortality
Magnetic Resonance Angiography
Subarachnoid Hemorrhage
Primary Prevention
Informed Consent
Spouses
Blood Vessels
Survivors
History
Genotype
Demography
Lymphocytes

ASJC Scopus subject areas

  • Medicine(all)
  • Genetics(clinical)
  • Genetics

Cite this

Broderick, J. P., Sauerbeck, L. R., Foroud, T., Huston, J., Pankratz, N., Meissner, I., & Brown, R. D. (2005). The Familial Intracranial Aneurysm (FIA) study protocol. BMC Medical Genetics, 6, [17]. https://doi.org/10.1186/1471-2350-6-17

The Familial Intracranial Aneurysm (FIA) study protocol. / Broderick, Joseph P.; Sauerbeck, Laura R.; Foroud, Tatiana; Huston, John; Pankratz, Nathan; Meissner, Irene; Brown, Robert D.

In: BMC Medical Genetics, Vol. 6, 17, 26.04.2005.

Research output: Contribution to journalArticle

Broderick, JP, Sauerbeck, LR, Foroud, T, Huston, J, Pankratz, N, Meissner, I & Brown, RD 2005, 'The Familial Intracranial Aneurysm (FIA) study protocol', BMC Medical Genetics, vol. 6, 17. https://doi.org/10.1186/1471-2350-6-17
Broderick JP, Sauerbeck LR, Foroud T, Huston J, Pankratz N, Meissner I et al. The Familial Intracranial Aneurysm (FIA) study protocol. BMC Medical Genetics. 2005 Apr 26;6. 17. https://doi.org/10.1186/1471-2350-6-17
Broderick, Joseph P. ; Sauerbeck, Laura R. ; Foroud, Tatiana ; Huston, John ; Pankratz, Nathan ; Meissner, Irene ; Brown, Robert D. / The Familial Intracranial Aneurysm (FIA) study protocol. In: BMC Medical Genetics. 2005 ; Vol. 6.
@article{5a2945f3efba418f8312902f05301db0,
title = "The Familial Intracranial Aneurysm (FIA) study protocol",
abstract = "Background: Subarachnoid hemorrhage (SAH) due to ruptured intracranial aneurysms (IAs) occurs in about 20,000 people per year in the U.S. annually and nearly half of the affected persons are dead within the first 30 days. Survivors of ruptured IAs are often left with substantial disability. Thus, primary prevention of aneurysm formation and rupture is of paramount importance. Prior studies indicate that genetic factors are important in the formation and rupture of IAs. The longterm goal of the Familial Intracranial Aneurysm (FIA) Study is to identify genes that underlie the development and rupture of intracranial aneurysms (IA). Methods/Design: The FIA Study includes 26 clinical centers which have extensive experience in the clinical management and imaging of intracerebral aneurysms. 475 families with affected sib pairs or with multiple affected relatives will be enrolled through retrospective and prospective screening of potential subjects with an IA. After giving informed consent, the proband or their spokesperson invites other family members to participate. Each participant is interviewed using a standardized questionnaire which covers medical history, social history and demographic information. In addition blood is drawn from each participant for DNA isolation and immortalization of lymphocytes. High- risk family members without a previously diagnosed IA undergo magnetic resonance angiography (MRA) to identify asymptomatic unruptured aneurysms. A 10 cM genome screen will be performed to identify FIA susceptibility loci. Due to the significant mortality of affected individuals, novel approaches are employed to reconstruct the genotype of critical deceased individuals. These include the intensive recruitment of the spouse and children of deceased, affected individuals. Discussion: A successful, adequately-powered genetic linkage study of IA is challenging given the very high, early mortality of ruptured IA. Design features in the FIA Study that address this challenge include recruitment at a large number of highly active clinical centers, comprehensive screening and recruitment techniques, non-invasive vascular imaging of high-risk subjects, genome reconstruction of dead affected individuals using marker data from closely related family members, and inclusion of environmental covariates in the statistical analysis.",
author = "Broderick, {Joseph P.} and Sauerbeck, {Laura R.} and Tatiana Foroud and John Huston and Nathan Pankratz and Irene Meissner and Brown, {Robert D.}",
year = "2005",
month = "4",
day = "26",
doi = "10.1186/1471-2350-6-17",
language = "English",
volume = "6",
journal = "BMC Medical Genetics",
issn = "1471-2350",
publisher = "BioMed Central",

}

TY - JOUR

T1 - The Familial Intracranial Aneurysm (FIA) study protocol

AU - Broderick, Joseph P.

AU - Sauerbeck, Laura R.

AU - Foroud, Tatiana

AU - Huston, John

AU - Pankratz, Nathan

AU - Meissner, Irene

AU - Brown, Robert D.

PY - 2005/4/26

Y1 - 2005/4/26

N2 - Background: Subarachnoid hemorrhage (SAH) due to ruptured intracranial aneurysms (IAs) occurs in about 20,000 people per year in the U.S. annually and nearly half of the affected persons are dead within the first 30 days. Survivors of ruptured IAs are often left with substantial disability. Thus, primary prevention of aneurysm formation and rupture is of paramount importance. Prior studies indicate that genetic factors are important in the formation and rupture of IAs. The longterm goal of the Familial Intracranial Aneurysm (FIA) Study is to identify genes that underlie the development and rupture of intracranial aneurysms (IA). Methods/Design: The FIA Study includes 26 clinical centers which have extensive experience in the clinical management and imaging of intracerebral aneurysms. 475 families with affected sib pairs or with multiple affected relatives will be enrolled through retrospective and prospective screening of potential subjects with an IA. After giving informed consent, the proband or their spokesperson invites other family members to participate. Each participant is interviewed using a standardized questionnaire which covers medical history, social history and demographic information. In addition blood is drawn from each participant for DNA isolation and immortalization of lymphocytes. High- risk family members without a previously diagnosed IA undergo magnetic resonance angiography (MRA) to identify asymptomatic unruptured aneurysms. A 10 cM genome screen will be performed to identify FIA susceptibility loci. Due to the significant mortality of affected individuals, novel approaches are employed to reconstruct the genotype of critical deceased individuals. These include the intensive recruitment of the spouse and children of deceased, affected individuals. Discussion: A successful, adequately-powered genetic linkage study of IA is challenging given the very high, early mortality of ruptured IA. Design features in the FIA Study that address this challenge include recruitment at a large number of highly active clinical centers, comprehensive screening and recruitment techniques, non-invasive vascular imaging of high-risk subjects, genome reconstruction of dead affected individuals using marker data from closely related family members, and inclusion of environmental covariates in the statistical analysis.

AB - Background: Subarachnoid hemorrhage (SAH) due to ruptured intracranial aneurysms (IAs) occurs in about 20,000 people per year in the U.S. annually and nearly half of the affected persons are dead within the first 30 days. Survivors of ruptured IAs are often left with substantial disability. Thus, primary prevention of aneurysm formation and rupture is of paramount importance. Prior studies indicate that genetic factors are important in the formation and rupture of IAs. The longterm goal of the Familial Intracranial Aneurysm (FIA) Study is to identify genes that underlie the development and rupture of intracranial aneurysms (IA). Methods/Design: The FIA Study includes 26 clinical centers which have extensive experience in the clinical management and imaging of intracerebral aneurysms. 475 families with affected sib pairs or with multiple affected relatives will be enrolled through retrospective and prospective screening of potential subjects with an IA. After giving informed consent, the proband or their spokesperson invites other family members to participate. Each participant is interviewed using a standardized questionnaire which covers medical history, social history and demographic information. In addition blood is drawn from each participant for DNA isolation and immortalization of lymphocytes. High- risk family members without a previously diagnosed IA undergo magnetic resonance angiography (MRA) to identify asymptomatic unruptured aneurysms. A 10 cM genome screen will be performed to identify FIA susceptibility loci. Due to the significant mortality of affected individuals, novel approaches are employed to reconstruct the genotype of critical deceased individuals. These include the intensive recruitment of the spouse and children of deceased, affected individuals. Discussion: A successful, adequately-powered genetic linkage study of IA is challenging given the very high, early mortality of ruptured IA. Design features in the FIA Study that address this challenge include recruitment at a large number of highly active clinical centers, comprehensive screening and recruitment techniques, non-invasive vascular imaging of high-risk subjects, genome reconstruction of dead affected individuals using marker data from closely related family members, and inclusion of environmental covariates in the statistical analysis.

UR - http://www.scopus.com/inward/record.url?scp=26444573828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26444573828&partnerID=8YFLogxK

U2 - 10.1186/1471-2350-6-17

DO - 10.1186/1471-2350-6-17

M3 - Article

VL - 6

JO - BMC Medical Genetics

JF - BMC Medical Genetics

SN - 1471-2350

M1 - 17

ER -